Normacor® is an innovative cardioplegic drug. Designed for performing normothermic open heart surgeries with cardiopulmonary bypass. Actual elimination of ischemia and reperfusion injuries provides a high degree of protection of the heart without limiting the duration of the surgery. It is possible to use the drug under hypothermia.

NORMACOR® belongs to the category of the drugs with proven safety and efficacy. In accordance with the current legislation of the Russian Federation, the drug has passed a comparative clinical study.

NORMACOR® (as the drug and trademark) is protected by the patents of the Russian Federation. The patents are being filed in other countries. 

NORMACOR® is the world's only cardioplegic drug developed for normothermic and hypothermic cardioplegia under cardiopulmonary bypass.


Welcome to our web site!
Please bear in mind that this project is intended for cardiology centers physicians and specialists only.

Are you a health professional?

Yes        No